We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+8.53%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$363M
AUM Growth
+$13.2M
Cap. Flow
+$3.91M
Cap. Flow %
1.08%
Top 10 Hldgs %
35.6%
Holding
94
New
25
Increased
21
Reduced
19
Closed
23

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$13.4M
2
BIIB icon
Biogen
BIIB
+$10.6M
3
UHS icon
Universal Health Services
UHS
+$9.83M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.37M
5
SNY icon
Sanofi
SNY
+$9.13M

Top Sells

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$10.9M
2
CRL icon
Charles River Laboratories
CRL
+$10.1M
3
MCK icon
McKesson
MCK
+$9.75M
4
CNC icon
Centene
CNC
+$9.59M
5
NVST icon
Envista
NVST
+$7.16M

Sector Composition

Rank Sector Weight
1 Healthcare 93.34%
2 Energy 2.32%
3 Industrials 1.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
51
BioMarin Pharmaceuticals
BMRN
$13.5B
$2.09M 0.57%
25,000
-27,000
-52% -$2.14M
UNH icon
52
UnitedHealth
UNH
$368B
$2M 0.55%
+5,000
New +$1.99M
BCRX icon
53
BioCryst Pharmaceuticals
BCRX
$2.65B
$1.98M 0.54%
125,000
-275,000
-69% -$3.74M
MYOV
54
DELISTED
Myovant Sciences Ltd.
MYOV
$1.94M 0.53%
85,000
+20,000
+31% +$421K
MCRB icon
55
Seres Therapeutics
MCRB
$49.6M
$1.79M 0.49%
+3,750
New +$1.58M
AGIO icon
56
Agios Pharmaceuticals
AGIO
$1.96B
$1.65M 0.46%
30,000
-13,000
-30% -$727K
ONEM
57
DELISTED
1Life Healthcare
ONEM
$1.65M 0.46%
+50,000
New +$1.89M
ALT icon
58
Altimmune
ALT
$599M
$1.58M 0.43%
+160,000
New +$2.19M
HRTX icon
59
Heron Therapeutics
HRTX
$61.5M
$1.55M 0.43%
+100,000
New +$1.59M
KPTI icon
60
Karyopharm Therapeutics
KPTI
$45.6M
$1.55M 0.43%
10,000
+6,667
+200% +$968K
AXGN icon
61
Axogen
AXGN
$2.61B
$1.51M 0.42%
+70,000
New +$1.41M
KURA icon
62
Kura Oncology
KURA
$880M
$1.46M 0.4%
70,000
+10,000
+17% +$248K
TRIL
63
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.46M 0.4%
+150,000
New +$1.41M
FMTX
64
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$1.12M 0.31%
+45,000
New +$1.21M
MSON
65
DELISTED
Misonix Inc
MSON
$998K 0.27%
45,000
– –
KDMN
66
DELISTED
Kadmon Holdings, Inc.
KDMN
$871K 0.24%
225,000
-75,000
-25% -$291K
DNTH icon
67
Dianthus Therapeutics
DNTH
$6.2B
$734K 0.2%
4,688
+625
+15% +$115K
ALEC icon
68
Alector
ALEC
$192M
$729K 0.2%
35,000
-20,000
-36% -$377K
CMRX
69
DELISTED
Chimerix, Inc.
CMRX
$600K 0.17%
+75,000
New +$624K
ARDX icon
70
Ardelyx
ARDX
$1B
$531K 0.15%
70,000
-25,000
-26% -$185K
LBPH
71
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$274K 0.08%
30,000
– –
ALLO icon
72
Allogene Therapeutics
ALLO
$725M
– –
-60,000
Closed -$2.12M
AMRN
73
Amarin Corp
AMRN
$301M
– –
-25,000
Closed -$3.1M
BDX icon
74
Becton Dickinson
BDX
$49.2B
– –
-20,500
Closed -$4.86M
BMY icon
75
Bristol-Myers Squibb
BMY
$132B
– –
-50,000
Closed -$3.16M
1 2
3
4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Integral Health Asset Management held 94 positions worth $363M, up 3.8% from $350M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Integral Health Asset Management's Q2 2021 filing shows 25 new, 21 increased, 19 reduced and 23 closed positions. Its largest new stake was Biogen: 35,000 shares worth $12.1M. The largest sale was Intellia Therapeutics, an estimated $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Energy and Industrials.

  • Integral Health Asset Management's largest Q2 2021 buy was Biogen: 35,000 shares worth $12.1M.
  • Integral Health Asset Management added most to Elevance Health in Q2 2021, an estimated $13.4M increase.
  • Integral Health Asset Management's biggest Q2 2021 reduction was Intellia Therapeutics, cutting an estimated $10.9M.
  • Integral Health Asset Management fully exited Charles River Laboratories in Q2 2021, selling an estimated $10.1M.
  • Integral Health Asset Management's ten largest holdings make up 36% of its $363M portfolio in Q2 2021.
  • Integral Health Asset Management opened 25 new positions and closed 23 in Q2 2021.
  • Integral Health Asset Management's portfolio value rose 3.8% quarter-over-quarter to $363M.

Based on Integral Health Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.